[1] |
D′Epiro S, Marocco C, Salvi M, et al. Psoriasis and bone mineral density: implications for long⁃term patients[J]. J Dermatol, 2014,41(9):783⁃787. doi: 10.1111/1346⁃8138.12546.
|
[2] |
Kathuria P, Gordon KB, Silverberg JI. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures[J]. J Am Acad Dermatol, 2017,76(6):1045⁃1053.e3. doi: 10.1016/j.jaad.2016.11.046.
|
[3] |
Manils J, Casas E, Viña⁃Vilaseca A, et al. The exonuclease Trex2 shapes psoriatic phenotype[J]. J Invest Dermatol, 2016,136(12):2345⁃2355. doi: 10.1016/j.jid.2016.05.122.
|
[4] |
Johansen C, Mose M, Ommen P, et al. IκBζ is a key driver in the development of psoriasis[J]. Proc Natl Acad Sci U S A, 2015,112(43):e5825⁃e5833. doi: 10.1073/pnas.1509971112.
|
[5] |
朱超英, 温炬, 李婷, 等. 白细胞介素36α对小鼠银屑病样皮损及趋化因子CCL20的影响[J]. 中华皮肤科杂志, 2017,50(4):263⁃267. doi: 10.3760/cma.j.issn.0412⁃4030.2017.04.007.
|
[6] |
Modalsli EH, Åsvold BO, Romundstad PR, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway[J]. Br J Dermatol, 2017,176(5):1162⁃1169. doi: 10.1111/bjd. 15123.
|
[7] |
Chandran S, Aldei A, Johnson SR, et al. Prevalence and risk factors of low bone mineral density in psoriatic arthritis: a systematic review[J]. Semin Arthritis Rheum, 2016,46(2):174⁃182. doi: 10.1016/j.semarthrit.2016.05.005.
|
[8] |
Chiricozzi A. Pathogenic role of IL⁃17 in psoriasis and psoriatic arthritis[J]. Actas Dermosifiliogr, 2014,105 Suppl 1:9⁃20. doi: 10.1016/S0001⁃7310(14)70014⁃6.
|
[9] |
Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL⁃17[J]. Cytokine Growth Factor Rev, 2015,26(1):25⁃33. doi: 10.1016/j.cytogfr.2014.10. 009.
|
[10] |
Weitzmann MN. Bone and the immune system[J]. Toxicol Pathol, 2017,45(7):911⁃924. doi: 10.1177/0192623317735316.
|
[11] |
Uluçkan Ö, Wagner EF. Role of IL⁃17A signalling in psoriasis and associated bone loss[J]. Clin Exp Rheumatol, 2016,34(4 Suppl 98):17⁃20.
|
[12] |
Adamopoulos IE, Suzuki E, Chao CC, et al. IL⁃17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis[J]. Ann Rheum Dis, 2015, 4(6):1284⁃1292. doi: 10.1136/annrheumdis⁃2013⁃204782.
|
[13] |
Burkett PR, Kuchroo VK. IL⁃17 blockade in psoriasis[J]. Cell, 2016,167(7):1669. doi: 10.1016/j.cell.2016.11.044.
|
[14] |
Mansoori MN, Shukla P, Singh D. Combination of PTH (1⁃34) with anti⁃IL17 prevents bone loss by inhibiting IL⁃17/N⁃cadherin mediated disruption of PTHR1/LRP⁃6 interaction[J]. Bone, 2017,105:226⁃236. doi: 10.1016/j.bone.2017.09.010.
|
[15] |
Theill LE, Boyle WJ, Penninger JM. RANK⁃L and RANK: T cells, bone loss, and mammalian evolution[J]. Annu Rev Immunol, 2002,20:795⁃823. doi: 10.1146/annurev.immunol.20. 100301.064753.
|
[16] |
Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss[J]. Gut, 2005,54(4):479⁃487. doi: 10.1136/gut.2004.044370.
|
[17] |
Pacifici R. T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone[J]. Ann N Y Acad Sci, 2016,1364:11⁃24. doi: 10.1111/nyas.12969.
|
[18] |
Xue Y, Jiang L, Cheng Q, et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions[J/OL]. PLoS One, 2012,7(10):e46740. [2019⁃01⁃08]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483160/. doi: 10. 1371/journal.pone.0046740.
|
[19] |
Attia EA, Khafagy A, Abdel⁃Raheem S, et al. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity[J]. Int J Dermatol, 2011,50(1):30⁃35. doi: 10.1111/j.1365⁃4632.2010.04600.x.
|
[20] |
Kotake S, Udagawa N, Takahashi N, et al. IL⁃17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis[J]. J Clin Invest, 1999,103(9):1345⁃1352. doi: 10.1172/JCI5703.
|
[21] |
Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction[J]. J Exp Med, 2006,203(12):2673⁃2682. doi: 10.1084/jem.20061775.
|
[22] |
Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin⁃1beta and tumor necrosis factor⁃alpha, but not interleukin⁃6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells[J]. Bone, 1999,25(3):255⁃259.
|
[23] |
Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T⁃cell production of TNF⁃alpha[J]. J Clin Invest, 2000,106(10):1229⁃1237. doi: 10.1172/JCI 11066.
|
[24] |
Bartosińska J, Michalak⁃Stoma A, Juszkiewicz⁃Borowiec M, et al. The assessment of selected bone and cartilage biomarkers in psoriatic patients from Poland[J/OL]. Mediators Inflamm, 2015,2015:194535. [2019⁃01⁃10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471390/. doi: 10.1155/2015/194535.
|